Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,394 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06612268RecruitingPhase 3
Etavopivat for reducing sickle cell pain crises
This study tests an investigational oral pill called etavopivat that may help reduce pain crises in people with sickle cell disease. You may qualify if you have frequent pain crises and are not on regular blood transfusions.
Birmingham, AlabamaAges 12 years+ - NCT06609226RecruitingPhase 3
Long-term safety study of etavopivat for sickle cell disease or thalassaemia
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
Birmingham, AlabamaAges 2 years+ - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Chandler, ArizonaAges 18–70 - NCT06603246RecruitingPhase 1
Study of inhaled GDC-6988 for mucus lung diseases
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Birmingham, AlabamaAges 18 years+ - NCT06601998Recruiting
Heart health after severe pneumonia
This study looks at how heart health changes in people who have recovered from severe pneumonia, including COVID-19. It compares survivors to healthy people and those with heart risk factors.
AlexandroupoliAges 18 years+ - NCT05776069RecruitingPhase 1/Phase 2
Test drug VGA039 for bleeding control in von Willebrand disease
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Los Angeles, CaliforniaAges 12–60 - NCT06585449RecruitingPhase 1
Study of ALN-HTT02 for Huntington's disease
This trial tests an experimental drug called ALN-HTT02 for people with Huntington's disease. The goal is to see if it can help manage symptoms. Participants must have stage 2 or early stage 3 Huntington's disease.
EdmontonAges 25–70 - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Birmingham, AlabamaAges 12 years+ - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06593951Recruiting
EPM1 natural history study
This study will follow people with EPM1 over time to better understand the disease. It is a registry, meaning you will share information through video calls and questionnaires, with no experimental treatments involved.
Boston, MassachusettsAges Any age - NCT06600178RecruitingPhase 1
Heart medication for women with chest pain and small vessel disease
This trial tests a diabetes medication called SGLT2 inhibitors to see if it can improve blood flow to the heart and reduce chest pain in women who have small vessel heart disease (microvascular dysfunction) but not blocked large arteries. Participants will take the medication and be monitored for symptom relief and heart function improvements.
Charlottesville, VirginiaAges 18 years+ - NCT06569758RecruitingPhase 1
A study of GenSci098 for active thyroid eye disease
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06581471Recruiting
New device for severe leaky heart valve
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
AalstAges 18 years+ - NCT06581042Recruiting
Study of upadacitinib in adults with IBD in Belgium
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
Bonheiden, AntwerpenAges 18 years+ - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
Birmingham, AlabamaAges 18–80 - NCT06582121Recruiting
Sleep disorders in early and advanced Parkinson's disease
This study looks at sleep problems in people with Parkinson's disease, people with REM sleep behavior disorder (a condition that causes acting out dreams), and healthy volunteers. The goal is to understand how sleep is affected in early and full Parkinson's disease.
Clermont-FerrandAges 18 years+ - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06555965Recruiting
STXBP1 and SYNGAP1 natural history study
This study follows people with STXBP1 or SYNGAP1 gene changes over time to learn more about how these conditions affect the body and mind. It does not test a treatment but helps researchers understand the natural course of the disorder.
Palo Alto, CaliforniaAges Any age - NCT06561919Recruiting
Speech and language study during brain stimulation treatment
This is an extra part of the STIMPulseControl study that focuses on speech. It looks at how the brain stimulation treatment affects your ability to speak clearly and communicate.
CologneAges 18–70 - NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Anaheim, CaliforniaAges 55 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06546670RecruitingPhase 1/Phase 2
Study of ITU512 for sickle cell disease
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
Birmingham, AlabamaAges 12–55
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,394 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.